GRK2 and heart failure: Three weeks post-gene transfer, GRK2 inhibition resulted in prevention of left ventricular (LV) adverse remodeling, improvement of cardiac contractility, and preservation of βAR signaling and function.16 Similarly, left ventricular remodeling was reversed by adeno-associated virus encoding for βARKct gene therapy in a pig model of heart failure.17 This and other studies make the βARKct a promising candidate for future application in human heart failure (Figure 1).